Risk and Severity of Hospital-Acquired Clostridium difficile Infection in Patients Taking Proton Pump Inhibitors

Area of Science:

• Infectious Diseases
• Gastroenterology
• Hospital Epidemiology

Background:

• Hospital-acquired Clostridium difficile infection (CDI) poses a significant clinical challenge.
• Proton pump inhibitors (PPIs) are widely prescribed medications with potential side effects.
• The association between PPI use and CDI risk requires further investigation.

Purpose of the Study:

• To compare the incidence and severity of hospital-acquired CDI in patients using PPIs versus those not using PPIs.
• To quantify the risk associated with PPI use for developing hospital-acquired and severe CDI.

Main Methods:

• Retrospective, single-center cohort study.
• Analysis of 41,663 patients with CDI hospitalized between January 2013 and May 2014.
• Comparison of hospital-acquired CDI rates and severity between PPI users (n=17,471) and non-users (n=24,192).

Main Results:

• Hospital-acquired CDI developed in 0.38% of PPI users versus 0.058% of non-users.
• Severe CDI occurred in 0.21% of PPI users versus 0.03% of non-users.
• PPI use was associated with a 6.46-fold increased risk of hospital-acquired CDI and a 6.27-fold increased risk of severe CDI.

Conclusions:

• Proton pump inhibitor use is significantly associated with an increased rate of hospital-acquired Clostridium difficile infection.
• PPI use is also linked to a higher severity of hospital-acquired CDI.
• These findings highlight a critical association between PPIs and adverse CDI outcomes.